Immune System Key

Drug Development for Malignant and Autoimmune Diseases

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in February 1992 by Dr. Yoram Devary and Prof. Uziel Sandler, Immune System Key operates with 1–10 employees. The company has raised $3.7 million across six funding rounds from the Office of the Chief Scientist. In November 2018, Immune System Key secured a new US patent for metastatic cancer treatment related to its lead compound, Nerofe.

Business overview

Immune System Key (ISK) is a Health Tech & Life Sciences company focused on the discovery and development of treatments for malignant cancers and autoimmune diseases. The company's core technology is based on novel human-secreted peptides, with a primary focus on acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer. Its lead compound, Nerofe, is designed to inhibit cancer progression by inducing anti-angiogenic effects and activating anticancer immune responses. ISK also develops diagnostic markers to predict treatment success, serving the pharmaceuticals and biotechnology sectors within the healthcare and life sciences markets globally.

Strategic signal

In November 2018, Immune System Key received a new US patent for metastatic cancer treatment, specifically for its lead compound, Nerofe. This patent validates the innovative potential of Nerofe in oncology, signaling a significant advancement in the company's intellectual property and its strategic position in developing therapies for challenging cancer types. For investors, this indicates progress in de-risking the drug development pipeline and enhancing the commercial viability of its therapeutic assets.

Company Intelligence Q&A

What is Immune System Key's primary focus in drug development?
Immune System Key is focused on the discovery and development of treatments for malignant cancers and autoimmune diseases, specifically targeting acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer.
What is Nerofe and what is its significance?
Nerofe is Immune System Key's lead compound, based on novel human-secreted peptides. It is designed to inhibit cancer progression by inducing a strong anti-angiogenic effect and activating an anticancer immune response. Nerofe was granted orphan status by the FDA for the treatment of AML.
When did Immune System Key receive a US patent for metastatic cancer treatment?
In November 2018, Immune System Key received a new US patent for metastatic cancer treatment related to its lead compound, Nerofe.
What was the outcome of the Phase 1 Nerofe trial for solid tumors?
In November 2017, Immune System Key successfully completed a Phase 1 Nerofe trial for solid tumors.
Who joined Immune System Key in April 2019?
In April 2019, Professor Marc E. Lippman, an expert in breast cancer, joined Immune System Key.

External links